

Jae Hoon Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8008916/publications.pdf>

Version: 2024-02-01

66
papers

562
citations

933447

10
h-index

642732

23
g-index

66
all docs

66
docs citations

66
times ranked

1077
citing authors

#	ARTICLE	IF	CITATIONS
1	The Radiographic Risk Factors Predicting Occurrence of Idiopathic Carpal Tunnel Syndrome in Simple Wrist X-ray. <i>Journal of Clinical Medicine</i> , 2022, 11, 4031.	2.4	1
2	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	1.6	3
3	Effect of herbal extracts on peripheral nerve regeneration after microsurgery of the sciatic nerve in rats. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 162.	2.7	3
4	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	1.8	5
5	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092104.	2.5	2
6	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721.	1.3	5
7	A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1312-1319.	2.0	8
8	A comparison of fasciocutaneous and adipofascial methods in the reverse sural artery flap for treatment of diabetic infected lateral malleolar bursitis. <i>Journal of Orthopaedic Surgery</i> , 2019, 27, 230949901982854.	1.0	8
9	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 92-95.	1.3	10
10	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018, 59, 2305-2317.	1.3	18
11	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
12	Onlay vascularized fibular grafting as a salvage procedure for the management of nonunion after reconstruction of the femur following tumor resection. <i>Journal of Orthopaedic Surgery</i> , 2018, 26, 230949901880249.	1.0	2
13	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	7.2	53
14	Factors affecting surgical outcomes of digital glomus tumour: a multicentre study. <i>Journal of Hand Surgery: European Volume</i> , 2018, 43, 652-658.	1.0	11
15	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017, 6, 100-108.	2.8	5
16	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
17	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	1.4	121
18	A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. <i>Cancer Genetics</i> , 2016, 209, 112-116.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	4
20	Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2014, 32, 8510-8510.	1.6	9
21	Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4421-4421.	1.4	0
22	A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 488-488.	1.6	4
23	A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3595-3595.	1.6	0
24	A phase II trial of a cremophor-free, polymeric micelle formulation of paclitaxel and gemcitabine in patients with advanced non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, e19129-e19129.	1.6	0
25	Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 269-277.	1.0	14
26	Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 687-695.	1.8	85
27	Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. <i>Journal of Clinical Oncology</i> , 2012, 30, 8095-8095.	1.6	9
28	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study. <i>Journal of Clinical Oncology</i> , 2012, 30, 8097-8097.	1.6	1
29	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). <i>Journal of Clinical Oncology</i> , 2012, 30, e18572-e18572.	1.6	5
30	A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e14137-e14137.	1.6	0
31	A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e14685-e14685.	1.6	0
32	High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study. <i>Blood</i> , 2012, 120, 1917-1917.	1.4	0
33	A Phase 1/2, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan As a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: Result of Phase 1 Trial. <i>Blood</i> , 2012, 120, 1937-1937.	1.4	1
34	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement. <i>Blood</i> , 2012, 120, 2683-2683.	1.4	0
35	Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome. <i>Blood</i> , 2012, 120, 2843-2843.	1.4	23
36	Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study. <i>Blood</i> , 2012, 120, 5035-5035.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer. <i>Journal of Lung Cancer</i> , 2011, 10, 49.	0.2	1
38	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1. <i>Blood</i> , 2011, 118, 3976-3976.	1.4	12
39	Mutational Analysis of N-Ras Proto-Oncogene in Acute Myeloid Leukemia: A Study of 70 Adult Korean Patients. <i>Blood</i> , 2011, 118, 4883-4883.	1.4	0
40	Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including <i>Campylobacter</i> Jejuni. <i>Blood</i> , 2011, 118, 5224-5224.	1.4	0
41	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia. <i>Blood</i> , 2011, 118, 3989-3989.	1.4	0
42	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010, 92, 52-57.	1.6	41
43	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP). <i>Blood</i> , 2009, 114, 1792-1792.	1.4	1
44	Efficacy of ICT with Deferasirox in Transfusional Iron Overloaded Patients with MDS or AA. <i>Blood</i> , 2009, 114, 3810-3810.	1.4	2
45	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study. <i>Blood</i> , 2009, 114, 4902-4902.	1.4	1
46	Osteonecrosis of the Jaw in Multiple Myeloma Patients: Incidence and Characteristics in Korean Patients. <i>Blood</i> , 2009, 114, 4956-4956.	1.4	1
47	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. <i>Blood</i> , 2009, 114, 743-743.	1.4	6
48	Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2009, 114, 2688-2688.	1.4	26
49	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP). <i>Blood</i> , 2009, 114, 4881-4881.	1.4	0
50	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea. <i>Blood</i> , 2009, 114, 5024-5024.	1.4	7
51	Evaluation of Platelet Indices for Differential Diagnosis of Thrombocytosis by ADVIA 120. <i>Blood</i> , 2009, 114, 4472-4472.	1.4	0
52	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 15. Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial. <i>Blood</i> , 2008, 112, 3330-3330.	1.4	22
53	A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 MRI. <i>Blood</i> , 2008, 112, 3649-3649.	1.4	4
54	Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. <i>Blood</i> , 2008, 112, 5184-5184.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Velcade® [®] , Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial. Blood, 2008, 112, 2785-2785.	1.4	0
56	Bortezomib, Doxorubicin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide and Dexamethasone (TD) as a Salvage Treatment for Relapsed Multiple Myeloma (MM): Analysis of Efficacy and Safety. Blood, 2008, 112, 5187-5187.	1.4	0
57	Final Report of "Korean Multicenter AML-2000 Trial": Intention to Treat Analysis Based on Cytogenetics Risk. Blood, 2008, 112, 2975-2975.	1.4	0
58	Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?. Blood, 2008, 112, 5146-5146.	1.4	0
59	The Assessment of IL-6R Gene Using FISH in MM.. Blood, 2007, 110, 4849-4849.	1.4	1
60	A Multicenter Comparison of Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation with Tandem Autologous Stem Cell Transplantation in Multiple Myeloma.. Blood, 2007, 110, 940-940.	1.4	1
61	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE® [®] , Thalidomide,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial.. Blood, 2007, 110, 952-952.	1.4	4
62	MTHFR 677CC/1298CC Genotypes Are Highly Associated with Chronic Myelogenous Leukemia: A Case-Control Study in Korea.. Blood, 2007, 110, 4533-4533.	1.4	0
63	Velcade® [®] , Thalidomide, Dexamethasone (VTD) Induction Therapy Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment for the Patients (pts) with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Early Analysis from the Korean Multiple Myeloma Working Party.. Blood, 2007, 110, 4831-4831.	1.4	0
64	Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.. Blood, 2007, 110, 4843-4843.	1.4	0
65	The Equal Activity of Azacytidine in 4 Risk Groups of IPSS in MDS.. Blood, 2007, 110, 4615-4615.	1.4	0
66	A Multicenter, Phase III Clinical Trial of Leucogreen® [®] (G-CSF) for Chemotherapy-Induced Neutropenia in Solid Tumors. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2003, 11, 38.	0.1	1